{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:19:02Z","timestamp":1789989542020,"version":"4.0.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,24]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Brief lenalidomide consolidation after chemoimmunotherapy is acceptably tolerated and extends PFS and OS in CLL. FCR has superior efficacy compared with FR chemoimmunotherapy for CLL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017015396","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T16:00:11Z","timestamp":1532102411000},"page":"1705-1718","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)"],"prefix":"10.1182","volume":"2","author":[{"given":"John C.","family":"Byrd","sequence":"first","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Division of Hematology,"},{"name":"Alliance Statistics and Data Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyla A.","family":"Heerema","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alese E.","family":"Halvorson","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoke","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Duke University, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, George Washington University Cancer Center, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Godwin","sequence":"additional","affiliation":[{"name":"Providence Cancer Center, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Couban","sequence":"additional","affiliation":[{"name":"QEII Health Sciences Centre, Halifax, NS, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Fehniger","sequence":"additional","affiliation":[{"name":"Division of Oncology, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thirman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Partners CancerCare, Harvard Cancer Center, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Robinson","sequence":"additional","affiliation":[{"name":"QEII Health Sciences Centre, Halifax, NS, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithra J.","family":"Mandrekar","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,7,20]]},"reference":[{"issue":"6","key":"2019111617232645500_B1","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"6","key":"2019111617232645500_B2","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"9403","key":"2019111617232645500_B3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","article-title":"ZAP-70 expression and prognosis in chronic lymphocytic leukaemia","volume":"363","author":"Orchard","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"2019111617232645500_B4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N Engl J Med"},{"issue":"7574","key":"2019111617232645500_B5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"26","key":"2019111617232645500_B6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111617232645500_B7","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia","volume":"338","author":"Dighiero","year":"1998","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111617232645500_B8","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"issue":"9013","key":"2019111617232645500_B9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia","volume":"347","author":"Johnson","year":"1996","journal-title":"Lancet"},{"issue":"8","key":"2019111617232645500_B10","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"issue":"5","key":"2019111617232645500_B11","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111617232645500_B12","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111617232645500_B13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111617232645500_B14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","article-title":"Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712","volume":"29","author":"Woyach","year":"2011","journal-title":"J Clin Oncol."},{"issue":"9747","key":"2019111617232645500_B15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"2019111617232645500_B16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.23993","article-title":"Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia","volume":"115","author":"Tsimberidou","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"2019111617232645500_B17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2019111617232645500_B18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111617232645500_B19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"6168","key":"2019111617232645500_B20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science."},{"issue":"11","key":"2019111617232645500_B21","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide [published correction appears in Leukemia. 2012;26(11):2445]","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"34","key":"2019111617232645500_B22","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111617232645500_B23","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111617232645500_B24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/10428194.2011.618232","article-title":"Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"53","author":"Wendtner","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2019111617232645500_B25","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","article-title":"Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia","volume":"26","author":"Andritsos","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111617232645500_B26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajh.23946","article-title":"Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)","volume":"90","author":"Maddocks","year":"2015","journal-title":"Am J Hematol"},{"issue":"20","key":"2019111617232645500_B27","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2012-12-470005","article-title":"Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)","volume":"121","author":"Shanafelt","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111617232645500_B28","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111617232645500_B29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.bloodjournal462219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"19","key":"2019111617232645500_B30","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111617232645500_B31","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/leu.2008.385","article-title":"A phase I\/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"23","author":"Woyach","year":"2009","journal-title":"Leukemia"},{"key":"2019111617232645500_B32","author":"Agresti","year":"1990"},{"issue":"2","key":"2019111617232645500_B33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J Royal Stat Soc. Series B"},{"issue":"1","key":"2019111617232645500_B34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"issue":"22","key":"2019111617232645500_B35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V128.22.230.230","article-title":"Results of the phase 3 study of lenalidomide versus placebo as maintenance therapy following second-line treatment for patients with chronic lymphocytic leukemia [abstract]","volume":"128","author":"Fo\u00e0","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111617232645500_B36","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1016\/S2352-3026(17)30171-0","article-title":"Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study","volume":"4","author":"Fink","year":"2017","journal-title":"Lancet Haematol"},{"issue":"22","key":"2019111617232645500_B37","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111617232645500_B38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"issue":"14","key":"2019111617232645500_B39","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-08-448332","article-title":"Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide","volume":"121","author":"Ramsay","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111617232645500_B40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/2326-6066.CIR-15-0291","article-title":"Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells","volume":"4","author":"Browning","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"2019111617232645500_B41","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2014-03-559591","article-title":"Lenalidomide inhibits the proliferation of CLL cells via a cereblon\/p21(WAF1\/Cip1)-dependent mechanism independent of functional p53","volume":"124","author":"Fecteau","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111617232645500_B42","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1182\/blood-2010-09-307140","article-title":"Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications","volume":"117","author":"Billot","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111617232645500_B43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111617232645500_B44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15","key":"2019111617232645500_B45","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111617232645500_B46","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111617232645500_B47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"13","key":"2019111617232645500_B48","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/14\/1705\/881002\/advances015396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/14\/1705\/881002\/advances015396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:22:33Z","timestamp":1720444953000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/14\/1705\/16235\/Lenalidomide-consolidation-benefits-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,20]]},"references-count":48,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,7,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017015396","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,20]]}}}